FDA Delays Nicotine Pouch Approvals Amid Youth Addiction Concerns
核心洞察
FDA scientists are hesitating to authorize popular nicotine pouch products under a fast-track scheme due to potential risks to new users, particularly children and non-tobacco users.
Applications from major tobacco companies including Philip Morris International (搜索)'s Zyn (搜索) and British American Tobacco's Velo (搜索) remain pending despite expectations for decisions by end of 2025.
The delays represent a significant blow to the $22 billion U.S. smoking alternatives market, with PMI shares falling over 7% following the news.
The Food and Drug Administration has delayed approvals for several major nicotine pouch brands despite implementing a fast-track review process, as agency scientists express concerns about potential addiction (搜索) risks to youth and non-tobacco users, according to three sources familiar with the regulatory process.
The delays affect pending applications from tobacco giants Philip Morris International (搜索) for newer versions of its top-selling Zyn (搜索) brand and British American Tobacco for its rival Velo (搜索) label. These products are part of the fastest-growing segment in the U.S. nicotine market, which is valued at approximately $22 billion.
Market Impact and Company Response
The regulatory uncertainty sent shockwaves through tobacco company valuations, with PMI shares falling more than 7% on Wednesday before recovering to close 4.8% lower. BAT stock declined 1.5%, while Turning Point Brands (搜索), which also has applications under review, plunged over 17%.
PMI alone sold 794 million cans of its current Zyn (搜索) version in the U.S. in 2025, more than doubling its 2023 sales figures. The company's market dominance in pouches has become a significant component of its valuation, making regulatory approval critical for future growth.
Regulatory Challenges and Scientific Concerns
The FDA's pilot program was designed to expedite decisions on outstanding applications, with approvals initially expected by the end of 2025. While six pouches under Altria (搜索)'s on! PLUS (搜索) label received licenses in December, applications for four other major brands remain in limbo.
Sources familiar with the review process indicate that scientific evidence supporting fast-track approval is "not as clear-cut as expected." Specific concerns center on risks to youth and the potential for driving addiction (搜索) in adults who do not currently use tobacco products.
The FDA's annual survey data shows that while nicotine pouch use among middle and high school students remains relatively low, it has increased in recent years. Agency reviewers are weighing this trend against the products' potential benefits for helping adult smokers transition to less harmful alternatives.
Regulatory Framework and Public Health Considerations
Under current regulations, new tobacco products must receive FDA authorization before legal sale in the United States. The agency evaluates whether products can help smokers switch to less harmful nicotine forms while minimizing risks to non-tobacco users and children.
The FDA acknowledges that nicotine products are highly addictive and not risk-free for adults, with particular concerns about nicotine's impact on developing brains. However, the agency also recognizes that pouches are generally less harmful than cigarettes and can lower health risks when smokers switch completely.
Industry Pressure and Market Dynamics
The pilot program emerged following pressure from tobacco lobbyists and the White House to authorize more brands for sale. Many manufacturers have had applications pending for years, forcing them to sell only outdated versions or operate without legal authorization while unregulated nicotine products flourish in the market.
BAT stated that its applications warrant FDA authorization given "robust scientific support" and emphasized continued constructive engagement with the agency. Both PMI and BAT argue that the pilot program could support public health goals while restoring fair competition in the U.S. nicotine market.
Anti-tobacco advocacy groups, including the Campaign for Tobacco-Free Kids, have expressed concerns that pouches' surging popularity and liberal marketing strategies could lead to increased youth usage. One source noted a "sizeable uptick" in pouch use among young adults, making the risk-benefit calculation more complex for regulators.
The FDA maintains that its decisions are based on science and law, declining to comment specifically on reviewer concerns about youth and new user risks. The agency confirmed that applications in the pilot program remain on track for faster decisions compared to standard review timelines.